Human Papillomavirus (HPV) E7 protein (49-57)

Product Name: Human Papillomavirus (HPV) E7 protein (49-57)

Sequence One Letter Code: RAHYNIVTF

Sequence Three Letter Code: H-Arg-Ala-His-Tyr-Asn-Ile-Val-Thr-Phe-OH

Chemical Formula:C52H77N15O13

Molecular Weight: 1120.3 Purity: 95% Form: Lyophilized

Storage Conditions: - 20 °C

Research Area: Cancer Disease Research

Source / Species: HPV

Conjugation: Unconjugated

Code Nacres: NA.26

Application: HPV E7 Protein (49–57) is a synthetic nonapeptide representing a defined cytotoxic T lymphocyte (CTL) epitope derived from the E7 oncoprotein of human papillomavirus. This peptide is restricted by the murine H-2Dᵇ MHC class I molecule and is extensively used in mouse tumor immunology models. It serves as a standardized antigen for evaluating antigen processing, MHC presentation, and CD8⁺ T cell activation. The peptide is widely applied in vaccine development research, adoptive T cell transfer studies, and tumor challenge assays to assess HPV-specific immune responses. Its well-characterized immunogenic profile makes it a reliable tool for investigating cellular immunity against HPV-associated malignancies and for benchmarking immunotherapeutic strategies in preclinical systems.

Current Research: HPV E7 Protein (49–57) is a synthetic nonapeptide corresponding to a defined cytotoxic T lymphocyte (CTL) epitope derived from the E7 oncoprotein of human papillomavirus (HPV). This peptide is restricted by the murine H-2Dᵇ MHC class I molecule and is extensively utilized in mouse tumor immunology models. Because the E7 oncoprotein is constitutively expressed in HPV-associated malignancies, this epitope serves as a standardized antigen for evaluating antigen presentation and CD8⁺ T cell–mediated immune responses. Immunological Context of E7 The HPV E7 protein is an oncogenic driver that disrupts cell cycle regulation through interaction with retinoblastoma (Rb) family proteins. Persistent expression of E7 in HPV-associated cancers, including cervical carcinoma and certain head and neck cancers, makes it an attractive target for immunotherapeutic intervention. The 49–57 peptide represents a well-characterized immunodominant epitope capable of eliciting strong CD8⁺ T cell responses in H-2Dᵇ–positive murine systems. MHC Class I Presentation HPV E7 (49–57) binds to the H-2Dᵇ MHC class I molecule, facilitating presentation on the surface of antigen-presenting cells. Recognition of this peptide–MHC complex by T cell receptors (TCRs) on CD8⁺ T cells triggers cytotoxic effector functions, including perforin and granzyme release, leading to antigen-specific tumor cell killing. Because of its defined MHC restriction and reproducible immunogenicity, this peptide is widely used to investigate: Antigen processing and cross-presentation pathways Peptide–MHC stability and binding affinity CD8⁺ T cell activation thresholds TCR specificity and avidity Applications in Tumor Immunology Models HPV E7 (49–57) is frequently employed in murine tumor challenge models using E7-expressing tumor cell lines (e.g., TC-1). These systems allow evaluation of antigen-specific immune responses and therapeutic strategies targeting HPV-driven malignancies. Applications include: Prophylactic and therapeutic vaccine studies Adoptive transfer of E7-specific CD8⁺ T cells Immune checkpoint blockade evaluation Assessment of tumor infiltration by antigen-specific lymphocytes Measurement of interferon-γ production via ELISPOT or intracellular staining The peptide serves as a consistent antigenic stimulus for benchmarking immunotherapeutic efficacy. Vaccine Development and Immunotherapy Research In vaccine development research, HPV E7 (49–57) is incorporated into peptide-based vaccines, DNA vaccines, viral vectors, and nanoparticle delivery systems. Its immunodominant nature enables reliable monitoring of antigen-specific responses following immunization. The peptide is also used to expand E7-specific T cells ex vivo for adoptive cell therapy studies, supporting mechanistic investigation of tumor antigen–directed immune responses. Experimental Advantages Defined H-2Dᵇ–restricted CTL epitope Strong and reproducible immunogenicity in murine models Compatible with MHC tetramer staining assays Suitable for in vitro stimulation and in vivo tumor challenge studies Standardized antigen for benchmarking immunotherapies Research Significance HPV E7 Protein (49–57) provides a robust and well-characterized antigenic tool for studying cellular immunity against HPV-associated cancers. Its defined MHC class I restriction and reproducible CD8⁺ T cell activation profile make it essential for evaluating antigen presentation, vaccine efficacy, adoptive T cell therapies, and immune checkpoint modulation in preclinical systems. As HPV-driven malignancies remain a significant clinical challenge, this peptide continues to support development and validation of immunotherapeutic strategies targeting viral oncogenes.